Letter to the editor: Comments on ‘A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation’

Meta H.M. Diekstra; Ruben Malmberg; Stefan Sleijfer; Roelof W.F. van Leeuwen

doi:10.1016/j.ejca.2020.07.014

Letter to the editor: Comments on ‘A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation’

Meta H.M. Diekstra, Ruben Malmberg, Stefan Sleijfer, Roelof W.F. van Leeuwen

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

2 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	54-56
Aantal pagina's	3
Tijdschrift	European Journal of Cancer
Volume	138
DOI's	https://doi.org/10.1016/j.ejca.2020.07.014
Status	Gepubliceerd - okt. 2020
Extern gepubliceerd	Ja

Toegang tot document

10.1016/j.ejca.2020.07.014

Citeer dit

@article{69d176ddb6f14f6dab59d869c3f554dd,

title = "Letter to the editor: Comments on {\textquoteleft}A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation{\textquoteright}",

keywords = "Antibodies, Monoclonal, Humanized, Computer Simulation, Humans, Neoplasms/drug therapy",

author = "Diekstra, {Meta H.M.} and Ruben Malmberg and Stefan Sleijfer and {van Leeuwen}, {Roelof W.F.}",

year = "2020",

month = oct,

doi = "10.1016/j.ejca.2020.07.014",

language = "English",

volume = "138",

pages = "54--56",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Letter to the editor

T2 - Comments on ‘A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation’

AU - Diekstra, Meta H.M.

AU - Malmberg, Ruben

AU - Sleijfer, Stefan

AU - van Leeuwen, Roelof W.F.

PY - 2020/10

Y1 - 2020/10

KW - Antibodies, Monoclonal, Humanized

KW - Computer Simulation

KW - Humans

KW - Neoplasms/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85089656030&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2020.07.014

DO - 10.1016/j.ejca.2020.07.014

M3 - Letter

C2 - 32854077

AN - SCOPUS:85089656030

SN - 0959-8049

VL - 138

SP - 54

EP - 56

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -